NASDAQ:IMNM Immunome (IMNM) Stock Price, News & Analysis $19.66 -0.24 (-1.21%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$19.76 +0.10 (+0.51%) As of 05/19/2026 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immunome Stock (NASDAQ:IMNM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immunome alerts:Sign Up Key Stats Today's Range$19.45▼$20.0250-Day Range$19.30▼$24.6352-Week Range$7.83▼$27.65Volume765,468 shsAverage Volume874,649 shsMarket Capitalization$2.23 billionP/E RatioN/ADividend YieldN/APrice Target$32.82Consensus RatingModerate Buy Company Overview Immunome, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles. The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens. In parallel, Immunome is advancing additional candidates in solid tumors, including antibody–drug conjugates and immunomodulatory antibodies that aim to stimulate anti-tumor immune responses. Beyond oncology, the platform has been applied to infectious disease programs, where candidate antibodies against emerging viral threats have been identified and optimized for potential therapeutic or prophylactic use. Founded in the early 2000s and headquartered in Ann Arbor, Michigan, Immunome has grown from a privately held research operation into a publicly traded company listed on the Nasdaq exchange under the ticker “IMNM.” In 2021, the company completed its initial public offering, providing capital to support ongoing clinical development and platform expansion. Led by President and Chief Executive Officer Greg Bailey, Immunome maintains collaborations with academic institutions and industry partners to advance its pipeline and explore new therapeutic applications of its discovery platform.AI Generated. May Contain Errors. Read More Immunome Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreIMNM MarketRank™: Immunome scored higher than 70% of companies evaluated by MarketBeat, and ranked 233rd out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingImmunome has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialImmunome has a consensus price target of $32.82, representing about 66.9% upside from its current price of $19.66.Amount of Analyst CoverageImmunome has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunome's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immunome are expected to grow in the coming year, from ($2.26) to ($2.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunome is -8.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunome is -8.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunome has a P/B Ratio of 3.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunome's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.76% of the float of Immunome has been sold short.Short Interest Ratio / Days to CoverImmunome has a short interest ratio ("days to cover") of 22.64, which indicates bearish sentiment.Change versus previous monthShort interest in Immunome has recently increased by 0.29%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunome does not currently pay a dividend.Dividend GrowthImmunome does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.79 News SentimentImmunome has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Immunome this week, compared to 3 articles on an average week.Search Interest2 people have searched for IMNM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Immunome to their MarketBeat watchlist in the last 30 days. Company Ownership2.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Immunome insiders have sold 2,270.78% more of their company's stock than they have bought. Specifically, they have bought $125,050.00 in company stock and sold $2,964,664.00 in company stock.Percentage Held by Insiders7.21% of the stock of Immunome is held by insiders.Percentage Held by Institutions44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunome's insider trading history. Receive IMNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMNM Stock News HeadlinesWhat Offers Immunome (IMNM) a Compelling Investment Opportunity?May 18 at 9:31 AM | insidermonkey.comAnalysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Coherus Biosciences (CHRS)May 15, 2026 | theglobeandmail.comYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - at no charge. Inside, he reveals the one options technique that took him 11 years to find, why more strategies often lead to more losses, and the 10-minute nightly routine that replaced his 8-hour trading days. | Profits Run (Ad)Analysts Are Bullish on Top Healthcare Stocks: Immunome (IMNM), Kalaris Therapeutics (KLRS)May 14, 2026 | theglobeandmail.comImmunome (NASDAQ:IMNM) Given "Buy" Rating at HC WainwrightMay 14, 2026 | americanbankingnews.comImmunome Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | businesswire.comImmunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid TumorsMay 11, 2026 | insidermonkey.comAssessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor SuccessMay 11, 2026 | finance.yahoo.comSee More Headlines IMNM Stock Analysis - Frequently Asked Questions How have IMNM shares performed this year? Immunome's stock was trading at $21.48 at the start of the year. Since then, IMNM stock has decreased by 8.5% and is now trading at $19.66. How were Immunome's earnings last quarter? Immunome, Inc. (NASDAQ:IMNM) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12. When did Immunome IPO? Immunome (IMNM) raised $39 million in an initial public offering on Thursday, October 1st 2020. The company issued 3,250,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO. Who are Immunome's major shareholders? Immunome's top institutional investors include Redmile Group LLC (4.91%), Enavate Sciences GP LLC (3.19%), Principal Financial Group Inc. (1.22%) and Readystate Asset Management LP (1.15%). Insiders that own company stock include Isaac Barchas, Clay B Siegall, Philip Wagenheim, Max Rosett, Jean Jacques Bienaime, Philip Tsai, Bruce Turner, Jack Higgins and Robert Lechleider. View institutional ownership trends. How do I buy shares of Immunome? Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunome own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/12/2026Today5/19/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 IMNM's financial health is in the Green zone, according to TradeSmith. IMNM has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMNM CIK1472012 Webimmunome.com Phone610-321-3700FaxN/AEmployees40Year Founded2008Price Target and Rating Average Price Target for Immunome$32.82 High Price Target$40.00 Low Price Target$22.00 Potential Upside/Downside+66.9%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$212.39 million Net MarginsN/A Pretax Margin-5,593.85% Return on Equity-51.15% Return on Assets-47.32% Debt Debt-to-Equity RatioN/A Current Ratio21.68 Quick Ratio21.68 Sales & Book Value Annual Sales$6.94 million Price / Sales320.82 Cash FlowN/A Price / Cash FlowN/A Book Value$5.20 per share Price / Book3.78Miscellaneous Outstanding Shares113,250,000Free Float105,085,000Market Cap$2.23 billion OptionableOptionable Beta2.11 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:IMNM) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
